BRIDGEBIO PHARMA INC
NASDAQ: BBIO (BridgeBio Pharma, Inc.)
Kemas kini terakhir: semalam, 11:55AM73.64
-1.12 (-1.50%)
| Penutupan Terdahulu | 74.76 |
| Buka | 74.40 |
| Jumlah Dagangan | 1,936,833 |
| Purata Dagangan (3B) | 2,310,778 |
| Modal Pasaran | 14,191,077,376 |
| Harga / Jualan (P/S) | 38.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2025 |
| Margin Operasi (TTM) | -89.00% |
| EPS Cair (TTM) | -3.56 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -44.80% |
| Nisbah Semasa (MRQ) | 4.57 |
| Aliran Tunai Operasi (OCF TTM) | -500.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -261.20 M |
| Pulangan Atas Aset (ROA TTM) | -48.27% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | BridgeBio Pharma, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.25 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.97% |
| % Dimiliki oleh Institusi | 98.14% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 110.00 (Cantor Fitzgerald, 49.38%) | Beli |
| Median | 87.00 (18.14%) | |
| Rendah | 71.00 (Raymond James, -3.59%) | Beli |
| Purata | 88.70 (20.45%) | |
| Jumlah | 10 Beli | |
| Harga Purata @ Panggilan | 62.11 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 11 Nov 2025 | 84.00 (14.07%) | Beli | 66.58 |
| JP Morgan | 07 Nov 2025 | 77.00 (4.56%) | Beli | 61.80 |
| HC Wainwright & Co. | 03 Nov 2025 | 90.00 (22.22%) | Beli | 61.98 |
| 29 Oct 2025 | 90.00 (22.22%) | Beli | 66.62 | |
| Goldman Sachs | 31 Oct 2025 | 100.00 (35.80%) | Beli | 62.64 |
| Cantor Fitzgerald | 30 Oct 2025 | 110.00 (49.38%) | Beli | 63.37 |
| Piper Sandler | 30 Oct 2025 | 98.00 (33.08%) | Beli | 63.37 |
| Raymond James | 30 Oct 2025 | 71.00 (-3.59%) | Beli | 63.37 |
| 21 Oct 2025 | 59.00 (-19.88%) | Beli | 54.36 | |
| TD Cowen | 30 Oct 2025 | 95.00 (29.01%) | Beli | 63.37 |
| Truist Securities | 30 Oct 2025 | 80.00 (8.64%) | Beli | 63.37 |
| UBS | 12 Sep 2025 | 82.00 (11.35%) | Beli | 51.21 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |